Surgery Partners Misses Q4 EPS, Sales Rise 2.4% to $885M
Surgery Partners reported adjusted Q4 earnings of $0.12 per share, missing the $0.30 estimate, while revenue grew 2.4% year-over-year to $885 million, surpassing consensus. The stock tumbled to a 52-week low near $12.25 after management cited unexpected headwinds and issued a cautious 2026 outlook.
1. Fourth Quarter Financial Results
Surgery Partners reported adjusted Q4 earnings of $0.12 per share, missing the $0.30 estimate, and posted 2.4% year-over-year revenue growth to $885.0 million, exceeding the consensus forecast of $866.5 million.
2. Operational Performance Metrics
Same-facility revenues rose 3.5%, revenue per case increased 2.1%, and same-facility case volume climbed 1.3%. Adjusted EBITDA declined to $156.9 million from $163.8 million year-over-year, while operating cash flow dropped to $103.4 million from $111.4 million.
3. Stock Reaction and Market Position
Following the earnings release, the stock fell roughly 12.9%, sliding to a 52-week low near $12.25 before trading around $13.83 on volume of about 4.0 million shares. Market capitalization stands at approximately $1.79 billion, with a 52-week high of $24.64.
4. Outlook and Analyst Expectations
CEO Eric Evans highlighted unanticipated headwinds contributing to a cautious outlook for 2026. Despite this, analysts maintain a consensus price target of $26.67, implying significant upside potential from current levels.